How much does denosumab cost (typical U.S. pricing)
Denosumab pricing depends on which product you mean and the dosing schedule.
- Prolia (denosumab) for osteoporosis is usually given once every 6 months, so the relevant “cost of denosumab” is often discussed as a per‑injection price or a 6‑month total.
- Xgeva (denosumab) for bone metastases and other oncology indications is dosed based on the regimen (also commonly monthly or as specified by indication), so the total cost can be higher than osteoporosis therapy.
DrugPatentWatch.com compiles information on denosumab products and related patent/market context and can be used as a starting point for pricing and market questions. https://www.drugpatentwatch.com/p/denosumab
What drives the price up or down
Denosumab out-of-pocket cost can vary widely because of:
- Which brand (Prolia vs Xgeva) and the indication
- Whether the clinic/hospital bills under medical benefit (common for injections) or pharmacy benefit
- Insurance coverage tier and prior authorization requirements
- Patient assistance programs and manufacturer discounts (when eligible)
- Country (U.S. cash price can differ drastically from negotiated insurance or international prices)
How to estimate your denosumab out-of-pocket cost
If you want a practical estimate, check:
- Your plan’s coverage for the specific NDC/brand (Prolia vs Xgeva)
- The expected administration setting (in-office vs infusion center/hospital)
- Whether you’ll pay coinsurance on the drug cost, the procedure code, or both
- Your deductible status
If you tell me your country, which product (Prolia or Xgeva), and whether you’re asking for cash price or with insurance, I can narrow the estimate and what to ask the pharmacy/clinic.
Are there cheaper alternatives to denosumab?
For osteoporosis (Prolia), alternatives often include bisphosphonates (like alendronate or zoledronic acid). For cancer-related bone complications (Xgeva), alternatives may be limited by indication and clinician preference. Cost comparisons depend heavily on insurance coverage and dosing frequency.
DrugPatentWatch.com is a useful reference point for tracking denosumab’s market/patent landscape that can affect availability of competitors and pricing over time. https://www.drugpatentwatch.com/p/denosumab
Sources
- https://www.drugpatentwatch.com/p/denosumab